Comparing Two Treatments for Aggressive Non-Hodgkin's Lymphoma
Author Information
Author(s): DC Linch, B Vaughan Hudson, BW Hancock, PJ Hoskin, DC Cunningham, AC Newland, DW Milligan, PA Stevenson, JK Wood, KA MacLennan, L Anderson, WM Gregory, G Vaughan Hudson
Primary Institution: British National Lymphoma Investigation
Hypothesis
Does the third-generation regimen PACEBOM provide better outcomes than the standard CHOP regimen for patients with aggressive non-Hodgkin's lymphoma?
Conclusion
The study found no significant difference in overall outcomes between the PACEBOM and CHOP regimens, although PACEBOM may offer some advantages for patients with stage IV disease.
Supporting Evidence
- The study included 459 patients, with 226 receiving CHOP and 233 receiving PACEBOM.
- Overall response rates showed 57% CR in CHOP and 64% CR in PACEBOM.
- The 5-year overall survival rates were 47% for CHOP and 56% for PACEBOM.
Takeaway
Doctors compared two treatments for a type of cancer called non-Hodgkin's lymphoma to see which one works better. They found that both treatments are pretty similar, but one might be a little better for patients with more advanced cancer.
Methodology
The study was a randomized trial comparing the CHOP and PACEBOM regimens in patients aged 16-69 with untreated aggressive lymphoma, assessing outcomes over several years.
Potential Biases
There were protocol violations in both treatment arms, which could affect the results.
Limitations
The study's subgroup analysis may not be reliable due to the small sample size and the potential for chance findings.
Participant Demographics
{"age":{"under_50":179,"over_50":280},"sex":{"male":285,"female":174},"stage":{"II":153,"III":106,"IV":200}}
Statistical Information
P-Value
p=0.23
Confidence Interval
{"CHOP":"39-56","PACEBOM":"48-63"}
Statistical Significance
p=0.23
Want to read the original?
Access the complete publication on the publisher's website